What specific regulatory approval has Sun Pharma received in South Africa for its generic semaglutide, and what is the approved indication?

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy; the approval is specifically for adults with inadequately controlled type 2 diabetes.

What are the key product details — dosage form, strengths, and administration frequency — of Sun Pharma's newly approved generic semaglutide in South Africa?

The drug will be sold as a pre-filled, multi-dose injectable pen in two strengths — 2 mg and 4 mg — for once-weekly use.

India's Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

Jul 15, 2026

Sun Pharma received South African regulatory approval to manufacture and sell a generic version of semaglutide, challenging Novo Nordisk and Eli Lilly in the diabetes and obesity drug market.

reuters

2026-07-15

India's Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

India's Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

FAQ